141 related articles for article (PubMed ID: 14634050)
21. Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).
Moreland RB; Nakane M; Donnelly-Roberts DL; Miller LN; Chang R; Uchic ME; Terranova MA; Gubbins EJ; Helfrich RJ; Namovic MT; El-Kouhen OF; Masters JN; Brioni JD
Biochem Pharmacol; 2004 Aug; 68(4):761-72. PubMed ID: 15276084
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons.
Sasaki T; Kotera J; Omori K
J Neurochem; 2004 Apr; 89(2):474-83. PubMed ID: 15056290
[TBL] [Abstract][Full Text] [Related]
23. Dexras1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase 1.
Nguyen CH; Watts VJ
Biochem Biophys Res Commun; 2005 Jul; 332(3):913-20. PubMed ID: 15913563
[TBL] [Abstract][Full Text] [Related]
24. Development of generic calcium imaging assay for monitoring Gi-coupled receptors and G-protein interaction.
Ueda T; Ugawa S; Ishida Y; Hondoh A; Shimada S
J Biomol Screen; 2009 Aug; 14(7):781-8. PubMed ID: 19541673
[TBL] [Abstract][Full Text] [Related]
25. RXFP1 couples to the Galpha-Gbetagamma-PI3K-PKCzeta pathway via the final 10 amino acids of the receptor C-terminal tail.
Halls ML; Papaioannou M; Wade JD; Evans BA; Bathgate RA; Summers RJ
Ann N Y Acad Sci; 2009 Apr; 1160():117-20. PubMed ID: 19416171
[TBL] [Abstract][Full Text] [Related]
26. Mastoparan inhibits beta-adrenoceptor-G(s) signaling by changing the localization of Galpha(s) in lipid rafts.
Sugama J; Yu JZ; Rasenick MM; Nakahata N
Cell Signal; 2007 Nov; 19(11):2247-54. PubMed ID: 17692506
[TBL] [Abstract][Full Text] [Related]
27. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
[TBL] [Abstract][Full Text] [Related]
28. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
[TBL] [Abstract][Full Text] [Related]
29. D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69.
Senogles SE
Anticancer Drugs; 2007 Aug; 18(7):801-7. PubMed ID: 17581302
[TBL] [Abstract][Full Text] [Related]
30. The influence of G protein subtype on agonist action at D2 dopamine receptors.
Nickolls SA; Strange PG
Neuropharmacology; 2004 Nov; 47(6):860-72. PubMed ID: 15527820
[TBL] [Abstract][Full Text] [Related]
31. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
Eldeeb K; Leone-Kabler S; Howlett AC
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
[TBL] [Abstract][Full Text] [Related]
32. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
33. The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats.
Chiang YC; Chen JC
J Neurochem; 2007 Dec; 103(6):2505-17. PubMed ID: 17953657
[TBL] [Abstract][Full Text] [Related]
34. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
35. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
Glass M; Felder CC
J Neurosci; 1997 Jul; 17(14):5327-33. PubMed ID: 9204917
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel site within G protein alpha subunits important for specificity of receptor-G protein interaction.
Heydorn A; Ward RJ; Jorgensen R; Rosenkilde MM; Frimurer TM; Milligan G; Kostenis E
Mol Pharmacol; 2004 Aug; 66(2):250-9. PubMed ID: 15266015
[TBL] [Abstract][Full Text] [Related]
37. Regulation of dopamine D-receptor activation in vivo by protein phosphatase 2B (calcineurin).
Adlersberg M; Hsiung SC; Glickstein SB; Liu KP; Tamir H; Schmauss C
J Neurochem; 2004 Aug; 90(4):865-73. PubMed ID: 15287892
[TBL] [Abstract][Full Text] [Related]
38. Loss of association between activated Galpha q and Gbetagamma disrupts receptor-dependent and receptor-independent signaling.
Evanko DS; Thiyagarajan MM; Takida S; Wedegaertner PB
Cell Signal; 2005 Oct; 17(10):1218-28. PubMed ID: 16038796
[TBL] [Abstract][Full Text] [Related]
39. Galpha(s) sensitizes human SH-SY5Y cells to apoptosis independently of the protein kinase A pathway.
Zhao C; Lai JS; Warsh JJ; Li PP
J Neurosci Res; 2006 Aug; 84(2):389-97. PubMed ID: 16673398
[TBL] [Abstract][Full Text] [Related]
40. Signal transduction of the CB1 cannabinoid receptor.
Turu G; Hunyady L
J Mol Endocrinol; 2010 Feb; 44(2):75-85. PubMed ID: 19620237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
